Literature DB >> 1669831

Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo.

S Jacobs1, P E Lønning, B Haynes, L Griggs, M Dowsett.   

Abstract

By modification of a recently developed method for separation of radio-labelled urinary oestrogens we were able to separate oestrogen metabolites and measure their isotope ratios in urine following injections of [3H]delta 4-androstenedione and [14C]oestrone. This method provides a useful tool for studying in vivo aromatisation of delta 4-androstenedione into oestrone in breast cancer patients before and during treatment with aromatase inhibitors.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1669831     DOI： 10.3109/14756369109030396

Source DB:  PubMed          Journal:  J Enzyme Inhib        ISSN： 1026-5457


  14 in total

Review 1.  Clinical pharmacokinetics of aromatase inhibitors and inactivators.

Authors:  Per Lønning
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Aromatase inhibitors and inactivators for breast cancer therapy.

Authors:  Per E Lønning
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 3.  Comprehensive pharmacology and clinical efficacy of aromatase inhibitors.

Authors:  V C Njar; A M Brodie
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

Review 4.  Risks and benefits of aromatase inhibitors in postmenopausal breast cancer.

Authors:  L B Michaud; A U Buzdar
Journal:  Drug Saf       Date:  1999-10       Impact factor: 5.606

5.  The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients.

Authors:  F A MacNeill; S Jacobs; M Dowsett; P E Lonning; T J Powles
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 6.  Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved.

Authors:  Per Eystein Lønning; Hans Petter Eikesdal
Journal:  Endocr Relat Cancer       Date:  2013-06-24       Impact factor: 5.678

Review 7.  The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum.

Authors:  P E Lønning
Journal:  Ann Oncol       Date:  2010-07-08       Impact factor: 32.976

8.  Multilocus analysis of SNP and metabolic data within a given pathway.

Authors:  Vessela N Kristensen; Anya Tsalenko; Jurgen Geisler; Anne Faldaas; Grethe Irene Grenaker; Ole Christian Lingjaerde; Ståle Fjeldstad; Zohar Yakhini; Per Eystein Lønning; Anne-Lise Børresen-Dale
Journal:  BMC Genomics       Date:  2006-01-13       Impact factor: 3.969

9.  Strength and weakness of phase I to IV trials, with an emphasis on translational aspects.

Authors:  Per Eystein Lønning
Journal:  Breast Cancer Res       Date:  2008-12-18       Impact factor: 6.466

10.  Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxyandrostenedione.

Authors:  D C Johannessen; H Adlercreutz; T Fotsis; P E Lønning
Journal:  Br J Cancer       Date:  1993-08       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.